Results 41 to 50 of about 924 (199)
ChemMedChem, Volume 18, Issue 9, May 2, 2023., 2023 Ruthenium(II)‐catalyzed cycloaddition (RuAAC) is a powerful way to access 1,5‐disubsituted and 1,4,5‐trisubstituted triazole DBOs with complete control of regioselectivity. The biological activity of di‐ and tri‐substituted DBOs gave promising activity against a hyperpermeable strain of Escherichia coli producing KPC‐2, and molecular docking showed ...
Flavie Bouchet +7 more
wiley +1 more source
Recommendations to Synthetize Old and New β-Lactamases Inhibitors: A Review to Encourage Further Production [PDF]
, 2022 open2The increasing emergence of bacteria producing β-lactamases enzymes (BLEs), able to inactivate the available β-lactam antibiotics (BLAs), causing the hydrolytic opening of their β-lactam ring, is one of the global major warnings.
Alfei, Silvana, Zuccari, Guendalina
core +1 more source
Case Reports in Infectious Diseases, Volume 2023, Issue 1, 2023., 2023 Carbapenem‐resistant Acinetobacter baumannii infection is a critically prioritized pathogen by the World Health Organization and a cause for growing concern due to increased mortality among hospitalised patients. Phrenic nerve palsy is a rare complication of herpes zoster infection of the C3, C4, and C5 nerve roots.
Yvonne Ayerki Nartey +5 more
wiley +1 more source
The rising dominance of microbiology: what to expect in the next 15 years?
Microbial Biotechnology, Volume 15, Issue 1, Page 110-128, January 2022., 2022 Microbial research could lead to the development of in‐situ and ex‐situ rapid microbial detection systems based on microbial dark matter in the next 15 years. As a result of this anticipated shift, microbial cultivation will rapidly rise, altering the diversity of microorganisms and underlying lineages.
Roshan Kumar +6 more
wiley +1 more source
Sulbactam-durlobactam in combination with aztreonam and carbapenems against carbapenem-resistant Acinetobacter baumannii: an assessment using the MIC-based broth disk elution. [PDF]
J Clin MicrobiolKoenig C, Nicolau DP, Asempa T.
europepmc +2 more sources
Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory
Antibiotics, 2023 The rapid emergence of multi-drug resistant Gram-negative pathogens has driven the introduction of novel β-lactam combination agents (BLCs) to the antibiotic market: ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem ...
Carmella Russo, Romney Humphries
doaj +1 more source
Superbugs or multidrug resistant microbes: A new threat to the society
, 2023 Health Science Reports, Volume 6, Issue 8, August 2023.
Sakshi Painuli +3 more
wiley +1 more source
Antimicrobial susceptibility to last-resort antibiotics in carbapenemase-producing bacteria from Ukrainian patients [PDF]
Since March 2022, an increase was observed in multidrug-resistant microorganisms (MDRO), associated with the hospital transfer of Ukrainian patients. The goal was to collect phenotypic susceptibility data and assess clinical implications.
+12 more
core +6 more sources
Clinical Infectious Diseases, 2023 Abstract Antimicrobial resistance in gram-negative pathogens, such as Acinetobacter baumannii, is a serious threat to human health. Sulbactam-durlobactam, a unique β-lactam and a β-lactamase inhibitor combination, is a novel agent targeted against carbapenem-resistant A. baumannii. This supplement provides a summary of the development of
Watkins, Richard R, Bonomo, Robert A
openaire +2 more sources
Antibiotics needed to treat multidrug-resistant infections in neonates. [PDF]
, 2022 Infections remain a leading cause of death in neonates. The sparse antibiotic development pipeline and challenges in conducting neonatal research have resulted in few effective antibiotics being adequately studied to treat multidrug-resistant (MDR ...
Agarwal, R +12 more
core +1 more source